Eli Lilly Reports Soaring Q1 Revenue & EPS, Raises Full-Year Guidance, and Secures Key FDA Approval
LLY sits 47% above its 52-week low of $623.78.
Summary
Eli Lilly reported outstanding Q1 2026 financial results with substantial revenue and EPS growth, raised its full-year guidance, and announced FDA approval for its new oral GLP-1 obesity drug, Foundayo.
Key Events · Earnings and Guidance · LLY
-
Exceptional Q1 Financial Performance
Revenue increased 56% to $19.8 billion, and reported EPS surged 170% to $8.26, driven by strong volume growth from Mounjaro and Zepbound.
-
Raised Full-Year Guidance
The company increased its 2026 full-year revenue guidance to a range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00.
-
FDA Approval of Foundayo
Received U.S. FDA approval for Foundayo (orforglipron), an oral GLP-1 pill for adults with obesity, offering a new, convenient treatment option.
-
Robust Pipeline Progress
Announced positive Phase 3 results for Foundayo in type 2 diabetes, Jaypirca in CLL/SLL, Taltz and Zepbound combination for psoriasis/obesity, and retatrutide in type 2 diabetes.
Analysis · LLY · Life Sciences
Eli Lilly delivered an exceptionally strong first quarter, significantly exceeding expectations with robust revenue and earnings growth driven by its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. The company's decision to raise its full-year revenue and EPS guidance signals continued confidence in its growth trajectory. Furthermore, the FDA approval of Foundayo, a new oral GLP-1 pill for obesity, represents a major strategic win, potentially expanding market access and solidifying Lilly's leadership in the metabolic health space. Investors should note the broad-based positive developments, including significant pipeline advancements and strategic acquisitions, which collectively reinforce a strong long-term outlook for the company.
At the time of this filing, LLY was trading at $914.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $804.2B. The 52-week trading range was $623.78 to $1,133.95. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.